<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32130630</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-6903</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Neurochemical research</Title><ISOAbbreviation>Neurochem Res</ISOAbbreviation></Journal><ArticleTitle>Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum.</ArticleTitle><Pagination><StartPage>1191</StartPage><EndPage>1201</EndPage><MedlinePgn>1191-1201</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11064-020-03002-5</ELocationID><Abstract><AbstractText>Exploring the neurochemical continuum between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) with respect to monoamines and kynurenines in cerebrospinal fluid (CSF) and serum, may be useful to identify possible new research/therapeutic targets. Hence, we analysed monoamines and kynurenines in CSF and serum derived from patients with FTD (n&#x2009;=&#x2009;39), ALS (n&#x2009;=&#x2009;23), FTD-ALS (n&#x2009;=&#x2009;4) and age-matched control subjects (n&#x2009;=&#x2009;26), using reversed-phase ultra-high performance liquid chromatography (RP-UHPLC) with electrochemical detection (ECD) and liquid chromatography tandem mass spectrometry, respectively. We noted a shared dopaminergic disturbance in FTD and ALS when compared to CONTR, with significantly increased serum DA levels and decreased DOPAC concentrations, as well as decreased DOPAC/DA ratios in both disease groups. In CSF, significantly reduced DOPAC concentrations in FTD and ALS were observed as well. Here, a significant increase in DA levels and decrease in DOPAC/DA ratios was only found in FTD relative to CONTR. With respect to the kynurenine pathway (KP), we only found decreased HK/XA ratios, indicative for vitamin B6 status, in serum of ALS subjects compared to FTD. The dopaminergic commonalities observed in FTD and ALS might relate to a disturbance of dopaminergic nerve terminals in projection areas of the substantia nigra and/or ventral tegmental area, although these findings should first be confirmed in brain tissue. Lastly, based on the results of this work, the KP does not hold promise as a research/therapeutic target in FTD and ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janssens</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Born-Bunge (IBB), University of Antwerp, Wilrijk, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Center Groningen, University Medical Center Groningen (UMCG) and University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeiren</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Born-Bunge (IBB), University of Antwerp, Wilrijk, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Center Groningen, University Medical Center Groningen (UMCG) and University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Faassen</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University Medical Center Groningen (UMCG) and University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Ley</LastName><ForeName>Claude</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University Medical Center Groningen (UMCG) and University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kema</LastName><ForeName>Ido P</ForeName><Initials>IP</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University Medical Center Groningen (UMCG) and University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Born-Bunge (IBB), University of Antwerp, Wilrijk, Antwerp, Belgium. p.p.de.deyn@umcg.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Center Groningen, University Medical Center Groningen (UMCG) and University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. p.p.de.deyn@umcg.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium. p.p.de.deyn@umcg.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ID20180027</GrantID><Agency>Alzheimer Research Foundation Belgium (SAO-FRA)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurochem Res</MedlineTA><NlmUniqueID>7613461</NlmUniqueID><ISSNLinking>0364-3190</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015306">Biogenic Monoamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>343-65-7</RegistryNumber><NameOfSubstance UI="D007737">Kynurenine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015306" MajorTopicYN="N">Biogenic Monoamines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007737" MajorTopicYN="N">Kynurenine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Neuropathology</Keyword><Keyword MajorTopicYN="N">Neurophysiology</Keyword></KeywordList><CoiStatement>The authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32130630</ArticleId><ArticleId IdType="pmc">PMC7162843</ArticleId><ArticleId IdType="doi">10.1007/s11064-020-03002-5</ArticleId><ArticleId IdType="pii">10.1007/s11064-020-03002-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chio A, Restagno G, Nicolaou N, Simon-Sanchez J, van Swieten JC, Abramzon Y, Johnson JO, Sendtner M, Pamphlett R, Orrell RW, Mead S, Sidle KC, Houlden H, Rohrer JD, Morrison KE, Pall H, Talbot K, Ansorge O, Chromosome ALSFTDC, French Research Network on FFA, Consortium I. Hernandez DG, Arepalli S, Sabatelli M, Mora G, Corbo M, Giannini F, Calvo A, Englund E, Borghero G, Floris GL, Remes AM, Laaksovirta H, McCluskey L, Trojanowski JQ, Van Deerlin VM, Schellenberg GD, Nalls MA, Drory VE, Lu CS, Yeh TH, Ishiura H, Takahashi Y, Tsuji S, Le Ber I, Brice A, Drepper C, Williams N, Kirby J, Shaw P, Hardy J, Tienari PJ, Heutink P, Morris HR, Pickering-Brown S, Traynor BJ. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Holtta-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chio A, Restagno G, Borghero G, Sabatelli M, Consortium I. Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T, van der Zee J, Gijselinck I, Engelborghs S, Vandenberghe R, Vandenbulcke M, De Bleecker J, Sieben A, Versijpt J, Ivanoiu A, Deryck O, Willems C, Dillen L, Philtjens S, Maes G, Baumer V, Van Den Broeck M, Mattheijssens M, Peeters K, Martin JJ, Michotte A, Santens P, De Jonghe P, Cras P, De Deyn PP, Cruts M, Van Broeckhoven C. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. JAMA Neurol. 2013;70(3):365&#x2013;373. doi: 10.1001/2013.jamaneurol.181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamaneurol.181</ArticleId><ArticleId IdType="pubmed">23338682</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VMY. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65(4):586&#x2013;590. doi: 10.1212/01.wnl.0000172911.39167.b6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000172911.39167.b6</ArticleId><ArticleId IdType="pubmed">16116120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheaton MW, Salamone AR, Mosnik DM, McDonald RO, Appel SH, Schmolck HI, Ringholz GM, Schulz PE. Cognitive impairment in familial ALS. Neurology. 2007;69(14):1411&#x2013;1417. doi: 10.1212/01.wnl.0000277422.11236.2c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000277422.11236.2c</ArticleId><ArticleId IdType="pubmed">17909153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Vignola A, Mastro E, Giudici AD, Iazzolino B, Calvo A, Moglia C, Montuschi A. Neurobehavioral symptoms in ALS are negatively related to caregivers' burden and quality of life. Eur J Neurol. 2010;17(10):1298&#x2013;1303. doi: 10.1111/j.1468-1331.2010.03016.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03016.x</ArticleId><ArticleId IdType="pubmed">20402747</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14(4):248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011;134(Pt 9):2582&#x2013;2594. doi: 10.1093/brain/awr195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr195</ArticleId><ArticleId IdType="pubmed">21840887</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T, Piguet O, Burrell JR, Leyton C, Foxe D, Abela M, Bartley L, Kim WS, Jary E, Huang Y, Dobson-Stone C, Kwok JB, Halliday GM, Hodges JR. Predicting development of amyotrophic lateral sclerosis in frontotemporal dementia. J Alzheimers Dis. 2017;58(1):163&#x2013;170. doi: 10.3233/JAD-161272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161272</ArticleId><ArticleId IdType="pubmed">28387671</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;3:CD001447. doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H, Edaravone ALSSG. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>The Writing Group on behalf of the Edaravone (MCI-186) ALS Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain. 2018;141(5):1263&#x2013;1285. doi: 10.1093/brain/awx327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx327</ArticleId><ArticleId IdType="pmc">PMC5917782</ArticleId><ArticleId IdType="pubmed">29373632</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjogren M, Minthon L, Passant U, Blennow K, Wallin A. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging. 1998;19(5):379&#x2013;384. doi: 10.1016/S0197-4580(98)00086-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(98)00086-4</ArticleId><ArticleId IdType="pubmed">9880039</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M, Marien P, Somers N, Nagels G, Pickut BA, De Deyn PP. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int. 2008;52(6):1052&#x2013;1060. doi: 10.1016/j.neuint.2007.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2007.10.018</ArticleId><ArticleId IdType="pubmed">18093695</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J, Vermeiren Y, Fransen E, Aerts T, Van Dam D, Engelborghs S, De Deyn PP. Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. Alzheimers Dement (Amst) 2018;10:172&#x2013;181. doi: 10.1016/j.dadm.2018.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2018.01.002</ArticleId><ArticleId IdType="pmc">PMC5852321</ArticleId><ArticleId IdType="pubmed">29552632</ArticleId></ArticleIdList></Reference><Reference><Citation>Heng B, Lim CK, Lovejoy DB, Bessede A, Gluch L, Guillemin GJ. Understanding the role of the kynurenine pathway in human breast cancer immunobiology. Oncotarget. 2016;7(6):6506&#x2013;6520. doi: 10.18632/oncotarget.6467.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6467</ArticleId><ArticleId IdType="pmc">PMC4872729</ArticleId><ArticleId IdType="pubmed">26646699</ArticleId></ArticleIdList></Reference><Reference><Citation>Sordillo PP, Sordillo LA, Helson L. The kynurenine pathway: a primary resistance mechanism in patients with glioblastoma. Anticancer Res. 2017;37(5):2159&#x2013;2171. doi: 10.21873/anticanres.11551.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.11551</ArticleId><ArticleId IdType="pubmed">28476779</ArticleId></ArticleIdList></Reference><Reference><Citation>Routy JP, Mehraj V, Vyboh K, Cao W, Kema I, Jenabian MA. Clinical relevance of kynurenine pathway in HIV/AIDS: an immune checkpoint at the crossroads of metabolism and inflammation. AIDS Rev. 2015;17(2):96&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">26035167</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Stankovic R, Cullen KM, Meininger V, Garner B, Coggan S, Grant R, Brew BJ, Guillemin GJ. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox Res. 2010;18(2):132&#x2013;142. doi: 10.1007/s12640-009-9129-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-009-9129-7</ArticleId><ArticleId IdType="pubmed">19921535</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L, Yu JT, Tan L. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci. 2012;323(1&#x2013;2):1&#x2013;8. doi: 10.1016/j.jns.2012.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2012.08.005</ArticleId><ArticleId IdType="pubmed">22939820</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddison DC, Giorgini F. The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol. 2015;40:134&#x2013;141. doi: 10.1016/j.semcdb.2015.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2015.03.002</ArticleId><ArticleId IdType="pubmed">25773161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilzecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand. 2003;107(6):412&#x2013;418. doi: 10.1034/j.1600-0404.2003.00076.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2003.00076.x</ArticleId><ArticleId IdType="pubmed">12757473</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546&#x2013;1554. doi: 10.1212/wnl.51.6.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeiren Y, Janssens J, Aerts T, Martin JJ, Sieben A, Van Dam D, De Deyn PP. Brain serotonergic and noradrenergic deficiencies in behavioral variant frontotemporal dementia compared to early-onset Alzheimer's disease. J Alzheimers Dis. 2016;53(3):1079&#x2013;1096. doi: 10.3233/JAD-160320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160320</ArticleId><ArticleId IdType="pubmed">27314528</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, Martin JJ, De Deyn PP. The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther. 2015;7(1):7. doi: 10.1186/s13195-014-0090-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-014-0090-1</ArticleId><ArticleId IdType="pmc">PMC4339739</ArticleId><ArticleId IdType="pubmed">25717350</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging. 2008;29(8):1143&#x2013;1159. doi: 10.1016/j.neurobiolaging.2007.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.016</ArticleId><ArticleId IdType="pubmed">17428581</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam D, Vermeiren Y, Aerts T, De Deyn PP. Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue. J Chromatogr A. 2014;1353:28&#x2013;39. doi: 10.1016/j.chroma.2014.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chroma.2014.05.004</ArticleId><ArticleId IdType="pubmed">24857034</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinitzer A, Tomaschitz A, Pilz S, Truber M, Zechner G, Gaksch M, Prietl B, Treiber G, Schwarz M, Baranyi A. Development of a liquid chromatography-mass spectrometry method for the determination of the neurotoxic quinolinic acid in human serum. Clin Chim Acta. 2014;436:268&#x2013;272. doi: 10.1016/j.cca.2014.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2014.06.010</ArticleId><ArticleId IdType="pubmed">24960364</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006;364(1&#x2013;2):82&#x2013;90. doi: 10.1016/j.cca.2005.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2005.06.013</ArticleId><ArticleId IdType="pubmed">16139256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciorba MA. Kynurenine pathway metabolites: relevant to vitamin B-6 deficiency and beyond. Am J Clin Nutr. 2013;98(4):863&#x2013;864. doi: 10.3945/ajcn.113.072025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.113.072025</ArticleId><ArticleId IdType="pmc">PMC4498264</ArticleId><ArticleId IdType="pubmed">23985806</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Pizzolato G, Bianchetti A, Chierichetti F, Ferlin G, Battistin L, Trabucchi M. Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results. Acta Neurol Scand. 1994;89(3):199&#x2013;203. doi: 10.1111/j.1600-0404.1994.tb01661.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1994.tb01661.x</ArticleId><ArticleId IdType="pubmed">8030401</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Laine M, Kaasinen V, Norvasuo-Heila MK, Nagren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002;58(10):1489&#x2013;1493. doi: 10.1212/wnl.58.10.1489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.58.10.1489</ArticleId><ArticleId IdType="pubmed">12034784</ArticleId></ArticleIdList></Reference><Reference><Citation>Borasio GD, Linke R, Schwarz J, Schlamp V, Abel A, Mozley PD, Tatsch K. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. J Neurol Neurosurg Psychiatry. 1998;65(2):263&#x2013;265. doi: 10.1136/jnnp.65.2.263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.65.2.263</ArticleId><ArticleId IdType="pmc">PMC2170216</ArticleId><ArticleId IdType="pubmed">9703186</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein DS, Holmes C, Sharabi Y. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain. 2012;135(Pt 6):1900&#x2013;1913. doi: 10.1093/brain/aws055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws055</ArticleId><ArticleId IdType="pmc">PMC3359749</ArticleId><ArticleId IdType="pubmed">22451506</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein DS, Holmes C, Lopez GJ, Wu T, Sharabi Y. Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease. Parkinsonism Relat Disord. 2018;50:108&#x2013;112. doi: 10.1016/j.parkreldis.2018.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2018.02.023</ArticleId><ArticleId IdType="pmc">PMC6319386</ArticleId><ArticleId IdType="pubmed">29475591</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen AD, Blaabjerg M, Binzer M, Kamal A, Thagesen H, Kjaer TW, Stenager E, Gramsbergen JBP. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. J Neurochem. 2017;141(4):614&#x2013;625. doi: 10.1111/jnc.13997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13997</ArticleId><ArticleId IdType="pubmed">28244186</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol. 1980;8(6):558&#x2013;563. doi: 10.1002/ana.410080603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410080603</ArticleId><ArticleId IdType="pubmed">6260009</ArticleId></ArticleIdList></Reference><Reference><Citation>Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7(3):255&#x2013;270. doi: 10.1038/nrd2468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2468</ArticleId><ArticleId IdType="pubmed">18219308</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K, Ohta Y, Nagai M, Morimoto N, Kurata T, Takehisa Y, Ikeda Y, Matsuura T, Abe K. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res. 2011;89(5):718&#x2013;728. doi: 10.1002/jnr.22594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22594</ArticleId><ArticleId IdType="pubmed">21337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Hertze J, Nagga K, Nilsson K, Nilsson C, Swedish Bio FSG, Wennstrom M, van Westen D, Blennow K, Zetterberg H, Hansson O. Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiol Aging. 2017;51:104&#x2013;112. doi: 10.1016/j.neurobiolaging.2016.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.11.017</ArticleId><ArticleId IdType="pmc">PMC5754327</ArticleId><ArticleId IdType="pubmed">28061383</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992;115(Pt 5):1249&#x2013;1273. doi: 10.1093/brain/115.5.1249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/115.5.1249</ArticleId><ArticleId IdType="pubmed">1422788</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bie J, Guest J, Guillemin GJ, Grant R. Central kynurenine pathway shift with age in women. J Neurochem. 2016;136(5):995&#x2013;1003. doi: 10.1111/jnc.13496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13496</ArticleId><ArticleId IdType="pubmed">26670548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S, Oda M, Tanabe H. Diminution of dopaminergic neurons in the substantia nigra of sporadic amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 1993;19(4):300&#x2013;304. doi: 10.1111/j.1365-2990.1993.tb00444.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1993.tb00444.x</ArticleId><ArticleId IdType="pubmed">7901781</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol. 1998;8(2):387&#x2013;402. doi: 10.1111/j.1750-3639.1998.tb00162.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.1998.tb00162.x</ArticleId><ArticleId IdType="pubmed">9546295</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>